Related Experiment Video

Updated: Jul 2, 2026

A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii
09:17

A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii

Published on: January 2, 2017

Pharmacokinetic and pharmacodynamic properties of meropenem

David P Nicolau1

  • 1Center for Anti-Infective Research and Development, Hartford Hospital, Hartford, Connecticut 06102, USA. dnicola@harthosp.org

Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|September 9, 2008
PubMed

Insights

Understanding meropenem dosing is crucial for effective treatment. Pharmacokinetic and pharmacodynamic modeling helps optimize antibiotic regimens, ensuring higher success rates for infections like meningitis.

Area of Science:

  • Pharmacology
  • Infectious Diseases
  • Clinical Pharmacy

Background:

  • Antibiotic dosing regimens require pharmacokinetic and pharmacodynamic (PK/PD) data for optimization.
  • Meropenem, a broad-spectrum antibiotic, exhibits time-dependent bactericidal activity.
  • Renal elimination of meropenem necessitates dose adjustments in patients with renal impairment.

Purpose of the Study:

  • To integrate pharmacokinetic and microbiological data for rational meropenem dosing strategies.
  • To characterize the pharmacodynamic profile of meropenem using the %T>MIC target.
  • To utilize pharmacodynamic modeling for identifying optimal meropenem regimens.

Main Methods:

  • Review of pharmacokinetic and pharmacodynamic principles of meropenem.
  • Analysis of meropenem's time-dependent bactericidal activity and the %T>MIC target (approximately 40%).
  • Application of pharmacodynamic modeling to predict the probability of achieving therapeutic targets.

Main Results:

  • Meropenem dosing requires consideration of its PK/PD profile, particularly renal elimination.
  • The pharmacodynamic target for meropenem is approximately 40%T>MIC.
  • Pharmacodynamic modeling can identify dosing regimens with a high probability of achieving the target.

Conclusions:

  • Integrating PK/PD data enables rational meropenem dosing strategies.
  • Pharmacodynamic modeling is a valuable tool for optimizing meropenem therapy.
  • Achieving the %T>MIC target is critical for effective meropenem treatment outcomes.

More Related Videos

Cystic Fibrosis Aggregate Biofilm Model to Study Infection-relevant Gene Expression08:58

Cystic Fibrosis Aggregate Biofilm Model to Study Infection-relevant Gene Expression

Published on: April 18, 2025

Related Concept Videos

Pharmacokinetic–Pharmacodynamic Relationship: Duration of Dose-Effect Relationship01:14

Pharmacokinetic–Pharmacodynamic Relationship: Duration of Dose-Effect Relationship

For drugs producing a quantal response, onset occurs when plasma concentration reaches a minimum effective level (Cmin). The drug's action duration depends on how long the plasma concentration remains above Cmin.Two primary factors influence this duration: dose size and the rate of drug removal from the action site. Both depend on the drug's redistribution to poorly perfused tissues and elimination processes. A larger dose promotes rapid onset and prolongs the effect's duration.Consider a...
Pharmacodynamic Models: Overview01:27

Pharmacodynamic Models: Overview

Pharmacodynamic (PD) responses describe the interaction between a drug and its biological target, culminating in a physiological effect. These responses can be classified into different types: continuous variables, such as blood glucose levels; categorical outcomes, like survival rates; and time-to-event metrics, such as disease progression. Understanding and modeling PD responses are critical for optimizing drug efficacy and safety.PD models describe the relationship between drug concentration...
Pharmacokinetic–Pharmacodynamic Relationship: Problems01:24

Pharmacokinetic–Pharmacodynamic Relationship: Problems

The empirical approach to drug therapy optimization relies on correlating pharmacological response with administered dosage. Such an approach can be costly, time-consuming, and often yields poor correlation due to variables like formulation factors and drug elimination characteristics. A more precise approach correlates response with plasma drug concentration or the amount of drug in the body, rather than dosage. This is achieved through pharmacokinetic-pharmacodynamic (PK/PD) modeling, which...
Pharmacokinetic–Pharmacodynamic Relationship: Influence of Elimination Half-Life on Effect Duration01:23

Pharmacokinetic–Pharmacodynamic Relationship: Influence of Elimination Half-Life on Effect Duration

Drug elimination from the body primarily occurs through metabolic and excretion pathways. Hepatic metabolism transforms lipophilic drugs into hydrophilic forms for excretion, typically via enzymatic processes classified as phase I (modification) and phase II (conjugation). Renal excretion eliminates drugs and metabolites through filtration and secretion in the kidneys. Impairment in liver or kidney function can hinder these processes, delaying drug clearance and extending the drug’s half-life.
Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance01:23

Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance

The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...
Pharmacokinetic–Pharmacodynamic Relationship: Model Components01:14

Pharmacokinetic–Pharmacodynamic Relationship: Model Components

Pharmacokinetic-pharmacodynamic (PK–PD) modeling is essential in drug development and clinical pharmacology. It provides a quantitative framework to predict drug behavior and response over time. This approach integrates pharmacokinetics (PK), which describes the drug's absorption, distribution, metabolism, and excretion, with pharmacodynamics (PD), which characterizes the drug’s biological effects and mechanisms of action.The disposition kinetics of a drug determine its plasma...